Bruker Corporation (NASDAQ:BRKR) Receives Average Rating of “Hold” from Brokerages

Shares of Bruker Corporation (NASDAQ:BRKR) have been given an average recommendation of “Hold” by the seventeen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $52.8571.

BRKR has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research report on Monday. The Goldman Sachs Group began coverage on Bruker in a research report on Tuesday, December 9th. They set a “sell” rating and a $40.00 price objective on the stock. Barclays boosted their target price on shares of Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday. Rothschild & Co Redburn assumed coverage on shares of Bruker in a report on Thursday, November 20th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Zacks Research raised shares of Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th.

Bruker Trading Down 1.2%

NASDAQ:BRKR opened at $44.41 on Friday. The firm has a 50-day simple moving average of $42.26 and a 200-day simple moving average of $38.49. Bruker has a one year low of $28.53 and a one year high of $64.64. The firm has a market cap of $6.75 billion, a P/E ratio of -277.56, a P/E/G ratio of 6.62 and a beta of 1.17. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.91 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company’s quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities analysts anticipate that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio is presently -125.00%.

Insider Activity at Bruker

In other news, Director John A. Ornell sold 6,233 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP increased its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Bruker by 9,800.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 4,851 shares of the medical research company’s stock worth $158,000 after buying an additional 4,802 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Bruker during the third quarter worth $321,000. Dark Forest Capital Management LP grew its holdings in shares of Bruker by 256.0% during the third quarter. Dark Forest Capital Management LP now owns 71,779 shares of the medical research company’s stock valued at $2,332,000 after buying an additional 51,614 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Bruker in the 3rd quarter valued at $589,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.